SCIENTURE HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Basic
SCIENTURE HOLDINGS, INC. (SCNX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$3.47 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-27.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2023-03-27
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-12-31 was -$925.19K.
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-09-30 was -$503.00K.
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-06-30 was -$1.08M.
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$960.15K.
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$3.47M.
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$5.32M.
- SCIENTURE HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$2.54M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$925.19K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$1.43M derived: sum of 2 quarters · filed 2023-03-27 | -$2.51M derived: sum of 3 quarters · filed 2023-03-27 | -$3.47M 10-K · filed 2023-03-27 |
| 2022-09-30 | -$503.00K 10-Q · filed 2022-11-07 | -$1.59M derived: sum of 2 quarters · filed 2022-11-07 | -$2.55M 10-Q · filed 2022-11-07 | -$3.33M derived: sum of 4 quarters · filed 2023-03-27 |
| 2022-06-30 | -$1.08M 10-Q · filed 2022-07-25 | -$2.04M 10-Q · filed 2022-07-25 | -$2.83M derived: sum of 3 quarters · filed 2023-03-27 | -$4.13M derived: sum of 4 quarters · filed 2023-03-27 |
| 2022-03-31 | -$960.15K 10-Q · filed 2022-05-09 | -$1.74M derived: sum of 2 quarters · filed 2023-03-27 | -$3.05M derived: sum of 3 quarters · filed 2023-03-27 | -$5.62M derived: sum of 4 quarters · filed 2023-03-27 |
| 2021-12-31 | -$784.34K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$2.09M derived: sum of 2 quarters · filed 2023-03-27 | -$4.66M derived: sum of 3 quarters · filed 2023-03-27 | -$5.32M 10-K · filed 2023-03-27 |
| 2021-09-30 | -$1.30M 10-Q · filed 2022-11-07 | -$3.88M derived: sum of 2 quarters · filed 2022-11-07 | -$4.53M 10-Q · filed 2022-11-07 | -$6.84M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$2.58M 10-Q · filed 2022-07-25 | -$3.23M 10-Q · filed 2022-07-25 | -$5.54M derived: sum of 3 quarters · filed 2022-07-25 | -$5.40M derived: sum of 4 quarters · filed 2022-07-25 |
| 2021-03-31 | -$651.52K 10-Q · filed 2022-05-09 | -$2.96M derived: sum of 2 quarters · filed 2022-05-09 | -$2.83M derived: sum of 3 quarters · filed 2022-05-09 | -$3.37M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$2.17M derived: sum of 2 quarters · filed 2022-03-28 | -$2.72M derived: sum of 3 quarters · filed 2022-03-28 | -$2.54M 10-K · filed 2022-03-28 |
| 2020-09-30 | $138.39K 10-Q · filed 2021-10-25 | -$404.20K derived: sum of 2 quarters · filed 2021-10-25 | -$223.89K 10-Q · filed 2021-10-25 | |
| 2020-06-30 | -$542.59K 10-Q · filed 2021-07-26 | -$362.28K 10-Q · filed 2021-07-26 | ||
| 2015-09-30 | -$123.76K 10-Q · filed 2015-11-02 | -$621.74K 10-Q · filed 2015-11-02 | ||
| 2014-09-30 | -$351.88K 10-Q · filed 2014-10-30 | -$644.02K derived: sum of 2 quarters · filed 2014-10-30 | -$1.57M 10-Q · filed 2014-10-30 | |
| 2014-06-30 | -$292.13K 10-Q · filed 2014-08-21 | -$1.19M 10-Q · filed 2014-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |